ArticleRegenerative therapy2020

Gaps between Asian regulations for eligibility of human mesenchymal stromal cells as starting materials of cell therapy products and comparability of mesenchymal stromal cell-based products subject to changes in their manufacturing process.

Toshimitsu Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.